(This abstract was borrowed from another version of this item.)"> (This abstract was borrowed from another version of this item.)">
Nothing Special   »   [go: up one dir, main page]
IDEAS home Printed from https://ideas.repec.org/p/hal/journl/halshs-02409743.html
   My bibliography  Save this paper

Research funding and price negotiation for new drugs

Author

Listed:
  • Francesca Barigozzi

    (UNIBO - Alma Mater Studiorum Università di Bologna = University of Bologna)

  • Izabela Jelovac

    (GATE Lyon Saint-Étienne - Groupe d'Analyse et de Théorie Economique Lyon - Saint-Etienne - ENS de Lyon - École normale supérieure de Lyon - UL2 - Université Lumière - Lyon 2 - UCBL - Université Claude Bernard Lyon 1 - Université de Lyon - UJM - Université Jean Monnet - Saint-Étienne - CNRS - Centre National de la Recherche Scientifique)

Abstract
Pharmaceutical innovations result from the successful achievement of basic research, produced by an upstream lab, and applied research, produced by a downstream lab. We focus on the negotiation process to finance basic research by setting public and private grants and to agree on the final price of a new drug. We show that exclusive funding of basic research is desirable. To increase consumers’ surplus and reduce negotiated prices for new drugs, basic and applied research should be integrated if the lab producing applied research has a relatively large bargaining power. When instead the health authority has the larger bargaining power, integration with the producer of basic research increases negotiated prices for new drugs and should be avoided, unless the gain in bargaining power after the integration is extremely high.
(This abstract was borrowed from another version of this item.)

Suggested Citation

  • Francesca Barigozzi & Izabela Jelovac, 2019. "Research funding and price negotiation for new drugs," Post-Print halshs-02409743, HAL.
    • Handle: RePEc:hal:journl:halshs-02409743
    as

    Download full text from publisher

    To our knowledge, this item is not available for download. To find whether it is available, there are three options:
    1. Check below whether another version of this item is available online.
    2. Check on the provider's web page whether it is in fact available.
    3. Perform a search for a similarly titled item that would be available.

    Other versions of this item:

    References listed on IDEAS

    as
    1. Catalina Martínez & Sarah Parlane, 2018. "On the firms’ decision to hire academic scientists," Working Papers 1801, Instituto de Políticas y Bienes Públicos (IPP), CSIC.
    2. Bardey, D. & Bommier, A. & Jullien, B., 2010. "Retail price regulation and innovation: Reference pricing in the pharmaceutical industry," Journal of Health Economics, Elsevier, vol. 29(2), pages 303-316, March.
    3. Philippe Aghion & Mathias Dewatripont & Jeremy C. Stein, 2008. "Academic freedom, private‐sector focus, and the process of innovation," RAND Journal of Economics, RAND Corporation, vol. 39(3), pages 617-635, September.
    4. Pierre Dubois & Olivier de Mouzon & Fiona Scott-Morton & Paul Seabright, 2015. "Market size and pharmaceutical innovation," RAND Journal of Economics, RAND Corporation, vol. 46(4), pages 844-871, October.
    5. González, Paula & Macho-Stadler, Inés & Pérez-Castrillo, David, 2016. "Private versus social incentives for pharmaceutical innovation," Journal of Health Economics, Elsevier, vol. 50(C), pages 286-297.
    6. Lacetera, Nicola & Zirulia, Lorenzo, 2012. "Individual preferences, organization, and competition in a model of R&D incentive provision," Journal of Economic Behavior & Organization, Elsevier, vol. 84(2), pages 550-570.
    7. Izabela Jelovac, 2015. "On the relationship between the negotiated prices of pharmaceuticals and the patients' co-payment," Economics Bulletin, AccessEcon, vol. 35(1), pages 481-493.
    8. Billette de Villemeur, Etienne & Versaevel, Bruno, 2019. "One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry," Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
    9. Wesley M. Cohen & Richard R. Nelson & John P. Walsh, 2003. "Links and Impacts: The Influence of Public Research on Industrial R&D," Chapters, in: Aldo Geuna & Ammon J. Salter & W. Edward Steinmueller (ed.), Science and Innovation, chapter 4, Edward Elgar Publishing.
    10. Gianni Fraja, 2016. "Optimal public funding for research: a theoretical analysis," RAND Journal of Economics, RAND Corporation, vol. 47(3), pages 498-528, August.
    11. Luigi Siciliani & Anderson Stanciole, 2013. "Bargaining and the provision of health services," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(3), pages 391-406, June.
    12. Billette de Villemeur, Etienne & Versaevel, Bruno, 2019. "One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry," Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
    Full references (including those not matched with items on IDEAS)

    Citations

    Blog mentions

    As found by EconAcademics.org, the blog aggregator for Economics research:
    1. Chris Sampson’s journal round-up for 28th December 2020
      by Chris Sampson in The Academic Health Economists' Blog on 2020-12-28 12:00:00

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Laura Grassi & Simone Fantaccini, 2022. "An overview of Fintech applications to solve the puzzle of health care funding: state-of-the-art in medical crowdfunding," Financial Innovation, Springer;Southwestern University of Finance and Economics, vol. 8(1), pages 1-27, December.
    2. Joan Costa‐Font & Rosella Levaggi, 2020. "Innovation, aging, and health care: Unraveling “silver” from “red” herrings?," Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 3-7, October.
    3. Thomas M. Fullerton & Steven L. Fullerton, 2022. "Aggregate Online Brand Name Pharmacy Price Dynamics for the United States and Mexico," Economies, MDPI, vol. 10(5), pages 1-5, May.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Simeth, Markus & Raffo, Julio D., 2013. "What makes companies pursue an Open Science strategy?," Research Policy, Elsevier, vol. 42(9), pages 1531-1543.
    2. repec:wip:wpaper:6 is not listed on IDEAS
    3. Catalina Martínez & Sarah Parlane, 2018. "On the firms’ decision to hire academic scientists," Working Papers 1801, Instituto de Políticas y Bienes Públicos (IPP), CSIC.
    4. Martínez, Catalina & Parlane, Sarah, 2023. "Academic scientists in corporate R&D: A theoretical model," Research Policy, Elsevier, vol. 52(5).
    5. Branstetter, Lee & Chatterjee, Chirantan & Higgins, Matthew J., 2022. "Generic competition and the incentives for early-stage pharmaceutical innovation," Research Policy, Elsevier, vol. 51(10).
    6. Bardey, David & Cremer, Helmuth & Lozachmeur, Jean-Marie, 2016. "The design of insurance coverage for medical products under imperfect competition," Journal of Public Economics, Elsevier, vol. 137(C), pages 28-37.
    7. Henry Sauermann & Michael Roach, 2011. "Not All Scientists pay to be Scientists:," DRUID Working Papers 11-03, DRUID, Copenhagen Business School, Department of Industrial Economics and Strategy/Aalborg University, Department of Business Studies.
    8. Timo Tohmo & Jutta Viinikainen, 2017. "Does intersectoral labour mobility pay for academics?," Scientometrics, Springer;Akadémiai Kiadó, vol. 113(1), pages 83-103, October.
    9. Brekke, Kurt R. & Dalen, Dag Morten & Straume, Odd Rune, 2022. "Paying for pharmaceuticals: uniform pricing versus two-part tariffs," Journal of Health Economics, Elsevier, vol. 83(C).
    10. Cisnetto, Valentina & Barlow, James, 2020. "The development of complex and controversial innovations. Genetically modified mosquitoes for malaria eradication," Research Policy, Elsevier, vol. 49(3).
    11. Kiri, Bralind & Lacetera, Nicola & Zirulia, Lorenzo, 2018. "Above a swamp: A theory of high-quality scientific production," Research Policy, Elsevier, vol. 47(5), pages 827-839.
    12. Gersbach, Hans & Schetter, Ulrich & Schmassmann, Samuel, 2023. "From local to global: A theory of public basic research in a globalized world," European Economic Review, Elsevier, vol. 160(C).
    13. Jürgen Janger, 2015. "Business Science Links For a New Growth Path. WWWforEurope Working Paper No. 107," WIFO Studies, WIFO, number 58413.
    14. Michaël Bikard & Keyvan Vakili & Florenta Teodoridis, 2019. "When Collaboration Bridges Institutions: The Impact of University–Industry Collaboration on Academic Productivity," Organization Science, INFORMS, vol. 30(2), pages 426-445, March.
    15. Kurt R. Brekke & Dag Morten Dalen & Odd Rune Straume, 2024. "Competing with precision: incentives for developing predictive biomarker tests," Scandinavian Journal of Economics, Wiley Blackwell, vol. 126(1), pages 60-97, January.
    16. Roach, Michael & Sauermann, Henry, 2010. "A taste for science? PhD scientists' academic orientation and self-selection into research careers in industry," Research Policy, Elsevier, vol. 39(3), pages 422-434, April.
    17. Billette de Villemeur, Etienne & Scannell, Jack & Versaevel, Bruno, 2021. "Biopharmaceutical R&D outsourcing: Short-term gain for long-term pain?," MPRA Paper 108233, University Library of Munich, Germany.
    18. Dosi, Giovanni & Palagi, Elisa & Roventini, Andrea & Russo, Emanuele, 2023. "Do patents really foster innovation in the pharmaceutical sector? Results from an evolutionary, agent-based model," Journal of Economic Behavior & Organization, Elsevier, vol. 212(C), pages 564-589.
    19. Jullien, Bruno & Lefouili, Yassine, 2018. "Horizontal Mergers and Innovation," CEPR Discussion Papers 12773, C.E.P.R. Discussion Papers.
    20. Steven Buccola & David Ervin & Hui Yang, 2009. "Research Choice and Finance in University Bioscience," Southern Economic Journal, John Wiley & Sons, vol. 75(4), pages 1238-1255, April.
    21. Quentin Plantec & Pascal Le Masson & Benoît Weil, 2022. "Mécanismes de découvertes – inventions dans la recherche industrielle : aux origines de CRISPR-Cas9 dans l’industrie agroalimentaire," Post-Print hal-03727323, HAL.

    More about this item

    JEL classification:

    • D8 - Microeconomics - - Information, Knowledge, and Uncertainty

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:hal:journl:halshs-02409743. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: CCSD (email available below). General contact details of provider: https://hal.archives-ouvertes.fr/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.